886 related articles for article (PubMed ID: 20197103)
1. Activated allogeneic NK cells as suppressors of alloreactive responses.
Hu B; He Y; Wu Y; Bao G; Liu H; Welniak LA; Murphy WJ
Biol Blood Marrow Transplant; 2010 Jun; 16(6):772-81. PubMed ID: 20197103
[TBL] [Abstract][Full Text] [Related]
2. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
3. Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
Hu B; Bao G; Zhang Y; Lin D; Wu Y; Wu D; Liu H
J Immunol; 2012 Aug; 189(4):1661-70. PubMed ID: 22798668
[TBL] [Abstract][Full Text] [Related]
4. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
5. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
6. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
8. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
[TBL] [Abstract][Full Text] [Related]
9. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
10. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
He KM; Ma Y; Wang S; Min WP; Zhong R; Jevnikar A; Zhang ZX
Eur J Immunol; 2007 Dec; 37(12):3455-66. PubMed ID: 18000953
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
12. A radio-resistant perforin-expressing lymphoid population controls allogeneic T cell engraftment, activation, and onset of graft-versus-host disease in mice.
Davis JE; Harvey M; Gherardin NA; Koldej R; Huntington N; Neeson P; Trapani JA; Ritchie DS
Biol Blood Marrow Transplant; 2015 Feb; 21(2):242-9. PubMed ID: 25459639
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of allogeneic liver sinusoidal endothelial cells specifically inhibits T-cell responses to cognate stimuli.
Banshodani M; Onoe T; Shishida M; Tahara H; Hashimoto S; Igarashi Y; Tanaka Y; Ohdan H
Cell Transplant; 2013; 22(9):1695-708. PubMed ID: 23050792
[TBL] [Abstract][Full Text] [Related]
14. Splenocytes cultured in low concentrations of IL-2 generate NK cell specificities toward syngenic and allogenic targets.
Nissen MH; Jeppesen M; Claesson MH
Cell Immunol; 2000 Jul; 203(1):47-54. PubMed ID: 10915561
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
16. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation.
Murphy WJ; Bennett M; Kumar V; Longo DL
J Immunol; 1992 May; 148(9):2953-60. PubMed ID: 1573278
[TBL] [Abstract][Full Text] [Related]
17. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic intrabone marrow-bone marrow transplantation plus donor lymphocyte infusion suppresses growth of colon cancer cells implanted in skin and liver of rats.
Koike Y; Adachi Y; Suzuki Y; Iwasaki M; Koike-Kiriyama N; Minamino K; Nakano K; Mukaide H; Shigematsu A; Kiyozuka Y; Tubura A; Kamiyama Y; Ikehara S
Stem Cells; 2007 Feb; 25(2):385-91. PubMed ID: 17284650
[TBL] [Abstract][Full Text] [Related]
19. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
20. Suppression of alloimmune cytotoxic T lymphocyte (CTL) generation by depletion of NK cells and restoration by interferon and/or interleukin 2.
Suzuki R; Suzuki S; Ebina N; Kumagai K
J Immunol; 1985 Apr; 134(4):2139-48. PubMed ID: 2579129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
